Earnings Feed
Sign Up
Home/Filings/3/0001104659-24-088483
3//SEC Filing

BIOS Fund III, LP 3

Accession 0001104659-24-088483

CIK 0001652935other
View on SEC.govCompany Profile

Filed

Aug 11, 8:00 PM ET

Accepted

Aug 12, 6:30 PM ET

Size

229.1 KB

Accession

0001104659-24-088483

Insider Transaction Report

Form 3
Period: 2024-08-12
ACTUATE THERAPEUTICS, INC.ACTU
Fletcher Aaron G.L.
Director10% Owner
Holdings

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II QP, LP)
    → Common Stock (462,073 underlying)

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II NT, LP)
    → Common Stock (61,857 underlying)

  • Common Stock

    (indirect: By Trust)
    8,056

  • Common Stock

    60,973

  • Common Stock

    (indirect: Directly held by BP Directors, LP)
    84,917

  • Common Stock

    (indirect: By Trust)
    8,056

  • Common Stock

    (indirect: Directly held by Circle K Invesco, LP)
    69,375

  • Convertible Note

    (indirect: Directly held by Bios Clinical Opportunity Fund, LP)
    → Common Stock

  • Series A Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund I, LP)
    → Common Stock (525,797 underlying)

  • Series A Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund I QP, LP)
    → Common Stock (307,538 underlying)

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II, LP)
    → Common Stock (141,457 underlying)

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest I, LP)
    → Common Stock (153,702 underlying)

  • Series B-3 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II QP, LP)
    → Common Stock (332,867 underlying)

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III NT, LP)
    → Common Stock (326,547 underlying)

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II, LP)
    → Common Stock (54,032 underlying)

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II QP, LP)
    → Common Stock (176,499 underlying)

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest I, LP)
    → Common Stock (147,047 underlying)

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II NT, LP)
    → Common Stock (23,628 underlying)

  • Series B-3 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II, LP)
    → Common Stock (101,900 underlying)

  • Series B-3 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II NT, LP)
    → Common Stock (44,559 underlying)

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III, LP)
    → Common Stock (309,589 underlying)

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III QP, LP)
    → Common Stock (2,022,029 underlying)

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest II, LP)
    → Common Stock (2,094,650 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III, LP)
    → Common Stock (74,202 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III NT, LP)
    → Common Stock (78,267 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III QP, LP)
    → Common Stock (484,638 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest III, LP)
    → Common Stock (573,394 underlying)

  • Series B Warrant (Right to Buy)

    (indirect: Directly held by Bios Fund II, LP)
    Exercise: $5.27From: 2018-09-07→ Common Stock (8,068 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II QP, LP)
    Exercise: $5.27From: 2018-09-07→ Common Stock (26,355 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II NT, LP)
    Exercise: $5.27From: 2018-09-07→ Common Stock (3,528 underlying)

  • Series B Warrant (Right to Buy)

    (indirect: Directly held by Bios Fund II, LP)
    Exercise: $10.54From: 2018-09-07→ Common Stock (8,068 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II QP, LP)
    Exercise: $10.54From: 2018-09-07→ Common Stock (26,355 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II NT, LP)
    Exercise: $10.54From: 2018-09-07→ Common Stock (3,528 underlying)

  • Stock Options

    (indirect: Directly held by BP Directors, LP)
    Exercise: $2.14Exp: 2033-04-29→ Common Stock (31,884 underlying)
BIOS Capital Management, LP
Director10% Owner
Holdings

  • Common Stock

    60,973

  • Common Stock

    (indirect: By Trust)
    8,056

  • Common Stock

    (indirect: By Trust)
    8,056

  • Common Stock

    (indirect: Directly held by BP Directors, LP)
    84,917

  • Common Stock

    (indirect: Directly held by Circle K Invesco, LP)
    69,375

  • Convertible Note

    (indirect: Directly held by Bios Clinical Opportunity Fund, LP)
    → Common Stock

  • Series A Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund I QP, LP)
    → Common Stock (307,538 underlying)

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II NT, LP)
    → Common Stock (61,857 underlying)

  • Series B-3 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II, LP)
    → Common Stock (101,900 underlying)

  • Series A Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund I, LP)
    → Common Stock (525,797 underlying)

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II, LP)
    → Common Stock (141,457 underlying)

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II QP, LP)
    → Common Stock (462,073 underlying)

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest I, LP)
    → Common Stock (153,702 underlying)

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II, LP)
    → Common Stock (54,032 underlying)

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II QP, LP)
    → Common Stock (176,499 underlying)

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II NT, LP)
    → Common Stock (23,628 underlying)

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest I, LP)
    → Common Stock (147,047 underlying)

  • Series B-3 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II NT, LP)
    → Common Stock (44,559 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II NT, LP)
    Exercise: $5.27From: 2018-09-07→ Common Stock (3,528 underlying)

  • Series B-3 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II QP, LP)
    → Common Stock (332,867 underlying)

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III, LP)
    → Common Stock (309,589 underlying)

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III QP, LP)
    → Common Stock (2,022,029 underlying)

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest II, LP)
    → Common Stock (2,094,650 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III, LP)
    → Common Stock (74,202 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III NT, LP)
    → Common Stock (78,267 underlying)

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III NT, LP)
    → Common Stock (326,547 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III QP, LP)
    → Common Stock (484,638 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest III, LP)
    → Common Stock (573,394 underlying)

  • Series B Warrant (Right to Buy)

    (indirect: Directly held by Bios Fund II, LP)
    Exercise: $5.27From: 2018-09-07→ Common Stock (8,068 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II QP, LP)
    Exercise: $5.27From: 2018-09-07→ Common Stock (26,355 underlying)

  • Series B Warrant (Right to Buy)

    (indirect: Directly held by Bios Fund II, LP)
    Exercise: $10.54From: 2018-09-07→ Common Stock (8,068 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II QP, LP)
    Exercise: $10.54From: 2018-09-07→ Common Stock (26,355 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II NT, LP)
    Exercise: $10.54From: 2018-09-07→ Common Stock (3,528 underlying)

  • Stock Options

    (indirect: Directly held by BP Directors, LP)
    Exercise: $2.14Exp: 2033-04-29→ Common Stock (31,884 underlying)
BIOS Advisors GP, LLC
Director10% Owner
Holdings

  • Common Stock

    60,973

  • Common Stock

    (indirect: By Trust)
    8,056

  • Common Stock

    (indirect: Directly held by Circle K Invesco, LP)
    69,375

  • Convertible Note

    (indirect: Directly held by Bios Clinical Opportunity Fund, LP)
    → Common Stock

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II, LP)
    → Common Stock (141,457 underlying)

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II QP, LP)
    → Common Stock (462,073 underlying)

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II NT, LP)
    → Common Stock (61,857 underlying)

  • Common Stock

    (indirect: Directly held by BP Directors, LP)
    84,917

  • Common Stock

    (indirect: By Trust)
    8,056

  • Series A Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund I, LP)
    → Common Stock (525,797 underlying)

  • Series A Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund I QP, LP)
    → Common Stock (307,538 underlying)

  • Series B-3 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II QP, LP)
    → Common Stock (332,867 underlying)

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III, LP)
    → Common Stock (309,589 underlying)

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III QP, LP)
    → Common Stock (2,022,029 underlying)

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III NT, LP)
    → Common Stock (326,547 underlying)

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest I, LP)
    → Common Stock (153,702 underlying)

  • Stock Options

    (indirect: Directly held by BP Directors, LP)
    Exercise: $2.14Exp: 2033-04-29→ Common Stock (31,884 underlying)

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II, LP)
    → Common Stock (54,032 underlying)

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II QP, LP)
    → Common Stock (176,499 underlying)

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II NT, LP)
    → Common Stock (23,628 underlying)

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest I, LP)
    → Common Stock (147,047 underlying)

  • Series B-3 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II, LP)
    → Common Stock (101,900 underlying)

  • Series B-3 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II NT, LP)
    → Common Stock (44,559 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III QP, LP)
    → Common Stock (484,638 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III NT, LP)
    → Common Stock (78,267 underlying)

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest II, LP)
    → Common Stock (2,094,650 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III, LP)
    → Common Stock (74,202 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest III, LP)
    → Common Stock (573,394 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II QP, LP)
    Exercise: $5.27From: 2018-09-07→ Common Stock (26,355 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II NT, LP)
    Exercise: $5.27From: 2018-09-07→ Common Stock (3,528 underlying)

  • Series B Warrant (Right to Buy)

    (indirect: Directly held by Bios Fund II, LP)
    Exercise: $10.54From: 2018-09-07→ Common Stock (8,068 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II QP, LP)
    Exercise: $10.54From: 2018-09-07→ Common Stock (26,355 underlying)

  • Series B Warrant (Right to Buy)

    (indirect: Directly held by Bios Fund II, LP)
    Exercise: $5.27From: 2018-09-07→ Common Stock (8,068 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II NT, LP)
    Exercise: $10.54From: 2018-09-07→ Common Stock (3,528 underlying)
BIOS Fund III, LP
Director10% Owner
Holdings

  • Series A Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund I, LP)
    → Common Stock (525,797 underlying)

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II QP, LP)
    → Common Stock (462,073 underlying)

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II NT, LP)
    → Common Stock (61,857 underlying)

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest I, LP)
    → Common Stock (153,702 underlying)

  • Common Stock

    60,973

  • Common Stock

    (indirect: By Trust)
    8,056

  • Common Stock

    (indirect: Directly held by Circle K Invesco, LP)
    69,375

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III QP, LP)
    → Common Stock (2,022,029 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III QP, LP)
    → Common Stock (484,638 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest III, LP)
    → Common Stock (573,394 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II QP, LP)
    Exercise: $5.27From: 2018-09-07→ Common Stock (26,355 underlying)

  • Common Stock

    (indirect: Directly held by BP Directors, LP)
    84,917

  • Common Stock

    (indirect: By Trust)
    8,056

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest I, LP)
    → Common Stock (147,047 underlying)

  • Series B-3 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II NT, LP)
    → Common Stock (44,559 underlying)

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III, LP)
    → Common Stock (309,589 underlying)

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III NT, LP)
    → Common Stock (326,547 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III NT, LP)
    → Common Stock (78,267 underlying)

  • Convertible Note

    (indirect: Directly held by Bios Clinical Opportunity Fund, LP)
    → Common Stock

  • Series A Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund I QP, LP)
    → Common Stock (307,538 underlying)

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II, LP)
    → Common Stock (141,457 underlying)

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II QP, LP)
    → Common Stock (176,499 underlying)

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II, LP)
    → Common Stock (54,032 underlying)

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II NT, LP)
    → Common Stock (23,628 underlying)

  • Series B-3 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II, LP)
    → Common Stock (101,900 underlying)

  • Series B-3 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II QP, LP)
    → Common Stock (332,867 underlying)

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest II, LP)
    → Common Stock (2,094,650 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III, LP)
    → Common Stock (74,202 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II NT, LP)
    Exercise: $10.54From: 2018-09-07→ Common Stock (3,528 underlying)

  • Series B Warrant (Right to Buy)

    (indirect: Directly held by Bios Fund II, LP)
    Exercise: $5.27From: 2018-09-07→ Common Stock (8,068 underlying)

  • Series B Warrant (Right to Buy)

    (indirect: Directly held by Bios Fund II, LP)
    Exercise: $10.54From: 2018-09-07→ Common Stock (8,068 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II NT, LP)
    Exercise: $5.27From: 2018-09-07→ Common Stock (3,528 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II QP, LP)
    Exercise: $10.54From: 2018-09-07→ Common Stock (26,355 underlying)

  • Stock Options

    (indirect: Directly held by BP Directors, LP)
    Exercise: $2.14Exp: 2033-04-29→ Common Stock (31,884 underlying)
BIOS Fund III QP, LP
Director10% Owner
Holdings

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest I, LP)
    → Common Stock (147,047 underlying)

  • Series B-3 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II QP, LP)
    → Common Stock (332,867 underlying)

  • Series B-3 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II NT, LP)
    → Common Stock (44,559 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II NT, LP)
    Exercise: $5.27From: 2018-09-07→ Common Stock (3,528 underlying)

  • Common Stock

    (indirect: By Trust)
    8,056

  • Common Stock

    (indirect: Directly held by BP Directors, LP)
    84,917

  • Common Stock

    60,973

  • Common Stock

    (indirect: By Trust)
    8,056

  • Common Stock

    (indirect: Directly held by Circle K Invesco, LP)
    69,375

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III, LP)
    → Common Stock (74,202 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III NT, LP)
    → Common Stock (78,267 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest III, LP)
    → Common Stock (573,394 underlying)

  • Convertible Note

    (indirect: Directly held by Bios Clinical Opportunity Fund, LP)
    → Common Stock

  • Series A Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund I, LP)
    → Common Stock (525,797 underlying)

  • Series A Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund I QP, LP)
    → Common Stock (307,538 underlying)

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II, LP)
    → Common Stock (141,457 underlying)

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II QP, LP)
    → Common Stock (462,073 underlying)

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II NT, LP)
    → Common Stock (61,857 underlying)

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest I, LP)
    → Common Stock (153,702 underlying)

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II QP, LP)
    → Common Stock (176,499 underlying)

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III QP, LP)
    → Common Stock (2,022,029 underlying)

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II, LP)
    → Common Stock (54,032 underlying)

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II NT, LP)
    → Common Stock (23,628 underlying)

  • Series B-3 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II, LP)
    → Common Stock (101,900 underlying)

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III, LP)
    → Common Stock (309,589 underlying)

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III NT, LP)
    → Common Stock (326,547 underlying)

  • Series B Warrant (Right to Buy)

    (indirect: Directly held by Bios Fund II, LP)
    Exercise: $5.27From: 2018-09-07→ Common Stock (8,068 underlying)

  • Series B Warrant (Right to Buy)

    (indirect: Directly held by Bios Fund II, LP)
    Exercise: $10.54From: 2018-09-07→ Common Stock (8,068 underlying)

  • Stock Options

    (indirect: Directly held by BP Directors, LP)
    Exercise: $2.14Exp: 2033-04-29→ Common Stock (31,884 underlying)

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest II, LP)
    → Common Stock (2,094,650 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III QP, LP)
    → Common Stock (484,638 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II NT, LP)
    Exercise: $10.54From: 2018-09-07→ Common Stock (3,528 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II QP, LP)
    Exercise: $5.27From: 2018-09-07→ Common Stock (26,355 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II QP, LP)
    Exercise: $10.54From: 2018-09-07→ Common Stock (26,355 underlying)
BIOS Equity Partners III, LP
Director10% Owner
Holdings

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II NT, LP)
    → Common Stock (61,857 underlying)

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III QP, LP)
    → Common Stock (2,022,029 underlying)

  • Common Stock

    (indirect: By Trust)
    8,056

  • Common Stock

    (indirect: Directly held by BP Directors, LP)
    84,917

  • Common Stock

    60,973

  • Common Stock

    (indirect: By Trust)
    8,056

  • Common Stock

    (indirect: Directly held by Circle K Invesco, LP)
    69,375

  • Convertible Note

    (indirect: Directly held by Bios Clinical Opportunity Fund, LP)
    → Common Stock

  • Series A Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund I QP, LP)
    → Common Stock (307,538 underlying)

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II QP, LP)
    → Common Stock (462,073 underlying)

  • Series A Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund I, LP)
    → Common Stock (525,797 underlying)

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II, LP)
    → Common Stock (141,457 underlying)

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II QP, LP)
    → Common Stock (176,499 underlying)

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest I, LP)
    → Common Stock (153,702 underlying)

  • Series B Warrant (Right to Buy)

    (indirect: Directly held by Bios Fund II, LP)
    Exercise: $5.27From: 2018-09-07→ Common Stock (8,068 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II NT, LP)
    Exercise: $5.27From: 2018-09-07→ Common Stock (3,528 underlying)

  • Stock Options

    (indirect: Directly held by BP Directors, LP)
    Exercise: $2.14Exp: 2033-04-29→ Common Stock (31,884 underlying)

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II, LP)
    → Common Stock (54,032 underlying)

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II NT, LP)
    → Common Stock (23,628 underlying)

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest I, LP)
    → Common Stock (147,047 underlying)

  • Series B-3 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II, LP)
    → Common Stock (101,900 underlying)

  • Series B-3 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II QP, LP)
    → Common Stock (332,867 underlying)

  • Series B-3 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II NT, LP)
    → Common Stock (44,559 underlying)

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III, LP)
    → Common Stock (309,589 underlying)

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III NT, LP)
    → Common Stock (326,547 underlying)

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest II, LP)
    → Common Stock (2,094,650 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III, LP)
    → Common Stock (74,202 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III QP, LP)
    → Common Stock (484,638 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III NT, LP)
    → Common Stock (78,267 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest III, LP)
    → Common Stock (573,394 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II QP, LP)
    Exercise: $5.27From: 2018-09-07→ Common Stock (26,355 underlying)

  • Series B Warrant (Right to Buy)

    (indirect: Directly held by Bios Fund II, LP)
    Exercise: $10.54From: 2018-09-07→ Common Stock (8,068 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II QP, LP)
    Exercise: $10.54From: 2018-09-07→ Common Stock (26,355 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II NT, LP)
    Exercise: $10.54From: 2018-09-07→ Common Stock (3,528 underlying)
BIOS Fund III NT, LP
Director10% Owner
Holdings

  • Common Stock

    (indirect: Directly held by BP Directors, LP)
    84,917

  • Common Stock

    (indirect: By Trust)
    8,056

  • Common Stock

    (indirect: By Trust)
    8,056

  • Series A Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund I, LP)
    → Common Stock (525,797 underlying)

  • Series A Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund I QP, LP)
    → Common Stock (307,538 underlying)

  • Common Stock

    60,973

  • Convertible Note

    (indirect: Directly held by Bios Clinical Opportunity Fund, LP)
    → Common Stock

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II, LP)
    → Common Stock (141,457 underlying)

  • Common Stock

    (indirect: Directly held by Circle K Invesco, LP)
    69,375

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II, LP)
    → Common Stock (54,032 underlying)

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II QP, LP)
    → Common Stock (462,073 underlying)

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest I, LP)
    → Common Stock (153,702 underlying)

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II NT, LP)
    → Common Stock (61,857 underlying)

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II QP, LP)
    → Common Stock (176,499 underlying)

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest I, LP)
    → Common Stock (147,047 underlying)

  • Series B-3 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II, LP)
    → Common Stock (101,900 underlying)

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II NT, LP)
    → Common Stock (23,628 underlying)

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III QP, LP)
    → Common Stock (2,022,029 underlying)

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III NT, LP)
    → Common Stock (326,547 underlying)

  • Series B Warrant (Right to Buy)

    (indirect: Directly held by Bios Fund II, LP)
    Exercise: $5.27From: 2018-09-07→ Common Stock (8,068 underlying)

  • Series B-3 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II QP, LP)
    → Common Stock (332,867 underlying)

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III, LP)
    → Common Stock (309,589 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III NT, LP)
    → Common Stock (78,267 underlying)

  • Series B-3 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II NT, LP)
    → Common Stock (44,559 underlying)

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest II, LP)
    → Common Stock (2,094,650 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III, LP)
    → Common Stock (74,202 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III QP, LP)
    → Common Stock (484,638 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest III, LP)
    → Common Stock (573,394 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II QP, LP)
    Exercise: $5.27From: 2018-09-07→ Common Stock (26,355 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II NT, LP)
    Exercise: $5.27From: 2018-09-07→ Common Stock (3,528 underlying)

  • Series B Warrant (Right to Buy)

    (indirect: Directly held by Bios Fund II, LP)
    Exercise: $10.54From: 2018-09-07→ Common Stock (8,068 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II QP, LP)
    Exercise: $10.54From: 2018-09-07→ Common Stock (26,355 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II NT, LP)
    Exercise: $10.54From: 2018-09-07→ Common Stock (3,528 underlying)

  • Stock Options

    (indirect: Directly held by BP Directors, LP)
    Exercise: $2.14Exp: 2033-04-29→ Common Stock (31,884 underlying)
BIOS Actuate Co-Invest I, LP
Director10% Owner
Holdings

  • Common Stock

    60,973

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II, LP)
    → Common Stock (141,457 underlying)

  • Common Stock

    (indirect: Directly held by BP Directors, LP)
    84,917

  • Series A Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund I QP, LP)
    → Common Stock (307,538 underlying)

  • Convertible Note

    (indirect: Directly held by Bios Clinical Opportunity Fund, LP)
    → Common Stock

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II QP, LP)
    → Common Stock (176,499 underlying)

  • Series B-3 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II, LP)
    → Common Stock (101,900 underlying)

  • Common Stock

    (indirect: By Trust)
    8,056

  • Common Stock

    (indirect: By Trust)
    8,056

  • Common Stock

    (indirect: Directly held by Circle K Invesco, LP)
    69,375

  • Series A Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund I, LP)
    → Common Stock (525,797 underlying)

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II QP, LP)
    → Common Stock (462,073 underlying)

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest I, LP)
    → Common Stock (153,702 underlying)

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II, LP)
    → Common Stock (54,032 underlying)

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II NT, LP)
    → Common Stock (61,857 underlying)

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II NT, LP)
    → Common Stock (23,628 underlying)

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest I, LP)
    → Common Stock (147,047 underlying)

  • Series B-3 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II QP, LP)
    → Common Stock (332,867 underlying)

  • Series B-3 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II NT, LP)
    → Common Stock (44,559 underlying)

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III, LP)
    → Common Stock (309,589 underlying)

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III QP, LP)
    → Common Stock (2,022,029 underlying)

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III NT, LP)
    → Common Stock (326,547 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III, LP)
    → Common Stock (74,202 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III NT, LP)
    → Common Stock (78,267 underlying)

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest II, LP)
    → Common Stock (2,094,650 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III QP, LP)
    → Common Stock (484,638 underlying)

  • Series B Warrant (Right to Buy)

    (indirect: Directly held by Bios Fund II, LP)
    Exercise: $10.54From: 2018-09-07→ Common Stock (8,068 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest III, LP)
    → Common Stock (573,394 underlying)

  • Series B Warrant (Right to Buy)

    (indirect: Directly held by Bios Fund II, LP)
    Exercise: $5.27From: 2018-09-07→ Common Stock (8,068 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II QP, LP)
    Exercise: $5.27From: 2018-09-07→ Common Stock (26,355 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II NT, LP)
    Exercise: $5.27From: 2018-09-07→ Common Stock (3,528 underlying)

  • Stock Options

    (indirect: Directly held by BP Directors, LP)
    Exercise: $2.14Exp: 2033-04-29→ Common Stock (31,884 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II QP, LP)
    Exercise: $10.54From: 2018-09-07→ Common Stock (26,355 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II NT, LP)
    Exercise: $10.54From: 2018-09-07→ Common Stock (3,528 underlying)
BIOS Actuate Co-Invest II, LP
Director10% Owner
Holdings

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II QP, LP)
    → Common Stock (176,499 underlying)

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II NT, LP)
    → Common Stock (23,628 underlying)

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest I, LP)
    → Common Stock (147,047 underlying)

  • Common Stock

    (indirect: By Trust)
    8,056

  • Common Stock

    (indirect: Directly held by BP Directors, LP)
    84,917

  • Common Stock

    (indirect: By Trust)
    8,056

  • Common Stock

    60,973

  • Common Stock

    (indirect: Directly held by Circle K Invesco, LP)
    69,375

  • Convertible Note

    (indirect: Directly held by Bios Clinical Opportunity Fund, LP)
    → Common Stock

  • Series A Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund I, LP)
    → Common Stock (525,797 underlying)

  • Series A Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund I QP, LP)
    → Common Stock (307,538 underlying)

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II, LP)
    → Common Stock (141,457 underlying)

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II QP, LP)
    → Common Stock (462,073 underlying)

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II NT, LP)
    → Common Stock (61,857 underlying)

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest I, LP)
    → Common Stock (153,702 underlying)

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II, LP)
    → Common Stock (54,032 underlying)

  • Series B-3 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II, LP)
    → Common Stock (101,900 underlying)

  • Series B-3 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II QP, LP)
    → Common Stock (332,867 underlying)

  • Series B-3 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II NT, LP)
    → Common Stock (44,559 underlying)

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III, LP)
    → Common Stock (309,589 underlying)

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III QP, LP)
    → Common Stock (2,022,029 underlying)

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III NT, LP)
    → Common Stock (326,547 underlying)

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest II, LP)
    → Common Stock (2,094,650 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III, LP)
    → Common Stock (74,202 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III QP, LP)
    → Common Stock (484,638 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III NT, LP)
    → Common Stock (78,267 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest III, LP)
    → Common Stock (573,394 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II NT, LP)
    Exercise: $10.54From: 2018-09-07→ Common Stock (3,528 underlying)

  • Stock Options

    (indirect: Directly held by BP Directors, LP)
    Exercise: $2.14Exp: 2033-04-29→ Common Stock (31,884 underlying)

  • Series B Warrant (Right to Buy)

    (indirect: Directly held by Bios Fund II, LP)
    Exercise: $5.27From: 2018-09-07→ Common Stock (8,068 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II QP, LP)
    Exercise: $5.27From: 2018-09-07→ Common Stock (26,355 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II NT, LP)
    Exercise: $5.27From: 2018-09-07→ Common Stock (3,528 underlying)

  • Series B Warrant (Right to Buy)

    (indirect: Directly held by Bios Fund II, LP)
    Exercise: $10.54From: 2018-09-07→ Common Stock (8,068 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II QP, LP)
    Exercise: $10.54From: 2018-09-07→ Common Stock (26,355 underlying)
Bios Actuate Co-Invest III, LP
Director10% Owner
Holdings

  • Common Stock

    (indirect: Directly held by Circle K Invesco, LP)
    69,375

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest II, LP)
    → Common Stock (2,094,650 underlying)

  • Common Stock

    (indirect: Directly held by BP Directors, LP)
    84,917

  • Common Stock

    60,973

  • Common Stock

    (indirect: By Trust)
    8,056

  • Common Stock

    (indirect: By Trust)
    8,056

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III, LP)
    → Common Stock (309,589 underlying)

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III QP, LP)
    → Common Stock (2,022,029 underlying)

  • Series B-4 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III NT, LP)
    → Common Stock (326,547 underlying)

  • Convertible Note

    (indirect: Directly held by Bios Clinical Opportunity Fund, LP)
    → Common Stock

  • Series A Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund I, LP)
    → Common Stock (525,797 underlying)

  • Series A Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund I QP, LP)
    → Common Stock (307,538 underlying)

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II, LP)
    → Common Stock (141,457 underlying)

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II QP, LP)
    → Common Stock (462,073 underlying)

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest I, LP)
    → Common Stock (153,702 underlying)

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II QP, LP)
    → Common Stock (176,499 underlying)

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest I, LP)
    → Common Stock (147,047 underlying)

  • Series B-1 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II NT, LP)
    → Common Stock (61,857 underlying)

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II, LP)
    → Common Stock (54,032 underlying)

  • Series B-2 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II NT, LP)
    → Common Stock (23,628 underlying)

  • Series B-3 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II, LP)
    → Common Stock (101,900 underlying)

  • Series B-3 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II QP, LP)
    → Common Stock (332,867 underlying)

  • Series B-3 Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund II NT, LP)
    → Common Stock (44,559 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II QP, LP)
    Exercise: $5.27From: 2018-09-07→ Common Stock (26,355 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III, LP)
    → Common Stock (74,202 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III QP, LP)
    → Common Stock (484,638 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Fund III NT, LP)
    → Common Stock (78,267 underlying)

  • Series C Redeemable Convertible Preferred Stock

    (indirect: Directly held by Bios Actuate Co-Invest III, LP)
    → Common Stock (573,394 underlying)

  • Series B Warrant (Right to Buy)

    (indirect: Directly held by Bios Fund II, LP)
    Exercise: $5.27From: 2018-09-07→ Common Stock (8,068 underlying)

  • Stock Options

    (indirect: Directly held by BP Directors, LP)
    Exercise: $2.14Exp: 2033-04-29→ Common Stock (31,884 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II NT, LP)
    Exercise: $5.27From: 2018-09-07→ Common Stock (3,528 underlying)

  • Series B Warrant (Right to Buy)

    (indirect: Directly held by Bios Fund II, LP)
    Exercise: $10.54From: 2018-09-07→ Common Stock (8,068 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II QP, LP)
    Exercise: $10.54From: 2018-09-07→ Common Stock (26,355 underlying)

  • Series B Warrants (Right to Buy)

    (indirect: Directly held by Bios Fund II NT, LP)
    Exercise: $10.54From: 2018-09-07→ Common Stock (3,528 underlying)
Footnotes (14)
  • [F1]Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("BP Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Actuate Co-Invest I, LP ("Bios Actuate Co-Invest I"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP"), Bios Fund III NT, LP ("Bios Fund III NT"), Bios Actuate Co-Invest II, LP ("Bios Actuate Co-Invest II") and Bios Actuate Co-Invest III, LP ("Bios Actuate Co-Invest III").
  • [F10]Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock will automatically convert into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock has no expiration date.
  • [F11]Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock will automatically convert into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock has no expiration date.
  • [F12]Each share of Series C Redeemable Convertible Preferred Stock preferred stock will automatically convert into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock has no expiration date.
  • [F13]The warrants are exercisable until the earliest to occur of (i) September 7, 2028, (ii) the consummation of a change in control of the Issuer and (iii) two years after the first closing of the Issuer's IPO. Upon the closing of the Issuer's IPO, each warrant shall automatically be exercised on a cashless basis if the exercise price is less than the initial public offering price.
  • [F14]The options are fully vested.
  • [F2]Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios Clinical Opportunity Fund, LP ("Bios COF"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP.
  • [F3]The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III and Bios COF (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively.
  • [F4]Shares are held in a trust, which has an independent trustee, for the benefit of Mr. Fletcher's children. Mr. Fletcher disclaims beneficial ownership of such shares other than to the extent he may have a pecuniary interest therein.
  • [F5]Shares are held by Circle K Invesco, LP, over which Mr. Kreis has sole voting and investment control.
  • [F6]Reflects a convertible note that is convertible into shares of common stock of the Issuer. The convertible note has a maturity date of July 31, 2024. The principal amount of the convertible note together with accrued interest will be automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering ("IPO") at a conversion price equal to the initial offering price multiplied by 0.8.
  • [F7]Each share of Series A Redeemable Convertible Preferred Stock preferred stock will automatically convert into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series A Convertible Preferred Stock has no expiration date.
  • [F8]Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock will automatically convert into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock has no expiration date.
  • [F9]Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock will automatically convert into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock has no expiration date.

Documents

2 files

Issuer

ACTUATE THERAPEUTICS, INC.

CIK 0001652935

→
Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001791917

Filing Metadata

Form type
3
Filed
Aug 11, 8:00 PM ET
Accepted
Aug 12, 6:30 PM ET
Size
229.1 KB
View on SEC.gov